当前位置: 首页 >> 检索结果
1. [Approaches in microsurgery for olfactory meningiomas: a systematic review and meta-analysis].
作者: A N Abdullaev.;R S Dzhindzhikhadze.;A V Polyakov.;V S Gadzhiagaev.;A D Zaitsev.;E I Salyamova.
来源: Zh Vopr Neirokhir Im N N Burdenko. 2026年90卷2期103-111页
Olfactory meningiomas are common neoplasms accounting for 4.5-18% of all intracranial meningiomas. Currently, transcranial (pterional, unilateral subfrontal, bilateral subfrontal, interhemispheric and through the frontal sinus) and endoscopic endonasal approaches are actively used.
2. [Efficacy and Side Effects of Lutetium-177 PSMA-617 in Patients with Castration Resistant Metastatic Prostate Cancer: A Systematic Review and Meta- analysis].
作者: Omar Fahmy Omar Fahmy.;Mohd Razaleigh Yusof Mohd Razaleigh Yusof.;Mohd Ghani Khairul Asri Mohd Ghani Khairul Asri.
来源: Urologiia. 2025年2期105-113页
Progression of metastatic prostate cancer after castration resistance is one of the main challenges in prostate cancer therapy. 177Lu-PSMA-617 has been recently investigated in castration resistant metastatic prostate cancer.
3. [Distal subtotal gastrectomy and gastreectomy in surgical treatment of patients with gastric cancer: a systematic review and meta-analysis].
作者: S I Panin.;M P Postolov.;N V Kovalenko.;A G Beburishvili.;A V Fedorov.;A V Bykov.
来源: Khirurgiia (Mosk). 2020年11期93-100页
To analyze the randomized controlled trials (RCTs) devoted to distal subtotal gastrectomy and gastrectomy with D2 lymphadenectomy in patients with distal gastric cancer.
4. [Meta-analysis of management of colorectal anastomotic leakage].
作者: Yu A Shelygin.;M A Nagudov.;A A Ponomarenko.;M V Alekseev.;E G Rybakov.;M A Tarasov.;S I Achkasov.
来源: Khirurgiia (Mosk). 2018年8. Vyp. 2期30-41页
To identify the most effective management of colorectal anastomosis failure via analysis of available literature sources.
5. [EPHX1 Tyr113His polymorphism contributes to hepatocellular carcinoma risk: evidfnce from a meta-analysis].
To clarify the association between microsomal epoxide hydrolase gene (EPHX1) Tyr113His polymorphism and hepatocellular carcinoma (HCC) risk, a meta-analysis was performed. Overall, EPHX1 Tyr113His polymorphism was associated with increased risk of HCC. Subgroup analyses by status of Hardy-Weinberg equilibrium (HWE) in controls further confirmed this association. Through a literature search, 119 relevant records were identified, and 17 individual case-control studies from 13 publications were finally included, involving a total of 1,480 HCC cases and 2,564 controls. In subgroup analyses, increased associations were found in Asians, Caucasians, hepatitis B virus (HBV)- dominant areas, hepatitis C virus (HCV)-dominant areas, high-rate areas of HCC, and medium-rate areas of HCC, but not in Africans and low-rate areas of HCC, respectively. This meta-analysis suggests that EPHX1 Tyr113His polymorphism contributes to HCC risk.
6. [Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer].
The paper discusses the results of phase II clinical trials of chemotherapy regimens using newly-developed cytostatics for disseminated small cell lung cancer. Taxotere (docetaxel)/cisplatin and campto(irinotecan)/cisplatin were investigated as first-line treatment. Doxorubicin and vincristine in combinations with a novel antitumor cytostatic aranoza were studied for application as second-line treatment. Safety and immediate- and end results were reviewed. Taxotere (docetaxel)/cisplatin and campto(irinotecan)/cisplatin regimens were compared.
|